Correlation between SPARC expression and clinical characteristics of esophageal squamous cell carcinoma

2013 â—½  
Vol 21 (21) â—½  
pp. 2081
Author(s):  
Yang Gao
Keyword(s):  
Squamous Cell Carcinoma â—½  
Esophageal Squamous Cell Carcinoma â—½  
Cell Carcinoma â—½  
Squamous Cell â—½  
Clinical Characteristics â—½  
Sparc Expression

Programmed cell death 1 expression in esophageal squamous cell carcinoma and association with clinical characteristics

2015 â—½  
Vol 52 (7) â—½  
pp. 176 â—½  
Author(s):  
L Li â—½  
Z Feng â—½  
Li Xiang-lei â—½  
W Hai-tao â—½  
W Zuo-pei â—½  
...  
Keyword(s):  
Squamous Cell Carcinoma â—½  
Cell Death â—½  
Programmed Cell Death â—½  
Esophageal Squamous Cell Carcinoma â—½  
Cell Carcinoma â—½  
Squamous Cell â—½  
Clinical Characteristics â—½  
Programmed Cell Death 1

scholarly journals Brain Metastases from Esophageal Squamous Cell Carcinoma: Clinical Characteristics and Prognosis

2021 â—½  
Vol 11 â—½  
Author(s):  
Linlin Xiao â—½  
Yvonne M. Mowery â—½  
Brian G. Czito â—½  
Yajing Wu â—½  
Guangbin Gao â—½  
...  
Keyword(s):  
Squamous Cell Carcinoma â—½  
Esophageal Squamous Cell Carcinoma â—½  
Brain Metastases â—½  
Supportive Care â—½  
Cell Carcinoma â—½  
Squamous Cell â—½  
Clinical Characteristics â—½  
Survival Rates â—½  
Locoregional Treatment

PurposeDue to the low incidence of intracranial disease among patients with esophageal cancer (EC), optimal management for these patients has not been established. The aim of this real-world study is to describe the clinical characteristics, treatment approaches, and outcomes for esophageal squamous cell carcinoma (ESCC) patients with brain metastases in order to provide a reference for treatment and associated outcomes of these patients.MethodsPatients with ESCC treated at the Fourth Hospital of Hebei Medical University between January 1, 2009 and May 31,2020 were identified in an institutional tumor registry. Patients with brain metastases were included for further analysis and categorized by treatment received. Survival was evaluated by the Kaplan-Meier method and Cox proportional hazards models.ResultsAmong 19,225 patients with ESCC, 66 (0.34%) were diagnosed with brain metastases. Five patients were treated with surgery, 40 patients were treated with radiotherapy, 10 with systemic therapy alone, and 15 with supportive care alone. The median follow-up time was 7.3 months (95% CI 7.4-11.4). At last follow-up, 59 patients are deceased and 7 patients are alive. Median overall survival (OS) from time of brain metastases diagnosis was 7.6 months (95% CI 5.3-9.9) for all cases. For patients who received locoregional treatment, median OS was 10.9 months (95% CI 7.4-14.3), and survival rates at 6 and 12 months were 75.6% and 37.2%, respectively. For patients without locoregional treatment, median OS was 3.0 months (95% CI 2.5-3.5), and survival rates at 6 and 12 months were 32% and 24%, respectively. OS was significantly improved for patients who received locoregional treatment compared to those treated with systematic treatment alone or supportive care (HR: 2.761, 95% CI 1.509-5.053, P=0.001). The median OS of patients with diagnosis-specific graded prognostic assessment (DS-GPA) score 0-2 was 6.4 months, compared to median OS of 12.3 months for patients with DS-GPA >2 (HR: 0.507, 95% CI 0.283-0.911).ConclusionBrain metastases are rare in patients with ESCC. DS-GPA score maybe a useful prognostic tool for ESCC patients with brain metastases. Receipt of locoregional treatment including brain surgery and radiotherapy was associated with improved survival.

Brain metastasis from esophageal squamous cell carcinoma: Clinical characteristics and prognosis.

2020 â—½  
Vol 38 (15_suppl) â—½  
pp. e16525-e16525
Author(s):  
Linlin Xiao â—½  
Yvonne Marie Mowery â—½  
Jun Wang â—½  
Min Zhao â—½  
Shaowu Jing â—½  
...  
Keyword(s):  
Squamous Cell Carcinoma â—½  
Brain Metastasis â—½  
Esophageal Squamous Cell Carcinoma â—½  
Cell Carcinoma â—½  
Squamous Cell â—½  
Clinical Characteristics â—½  
Malignant Tumors â—½  
Care Group â—½  
Esophageal Tumor â—½  
Radiotherapy Group

e16525 Background: Esophageal squamous cell carcinoma (ESCC) is one of the most common malignant tumors in China, but brain metastasis is rare and less reported. The aim of this study is to investigate the clinical characteristics and outcomes of ESCC patients with brain metastasis, so as to provide some references for them. Methods: Between January 1, 2009 and December 31, 2018, 16480 patients with ESCC were registered at the Fourth Hospital of Hebei Medical University. A total of 52 patients (0.32%) were diagnosed of brain metastasis. Thirty-two patients received craniocerebral radiotherapy, of them, 17 cases were treated with radiotherapy alone, the rest were treated with chemotherapy (n = 12) or targeted therapy(n = 13) concurrently. There were 6 patients received chemotherapy (platinum + docetaxel / paclitaxel) alone, and 14 cases received support therapy only. Results: The median interval time from the date of diagnosis of the primary tumor until diagnosis of brain metastasis was 9.2 months (range, 0-249.2 months). The initial stages of the patients in II, III and IV were 6, 25 and 21, respectively. The median length of esophageal tumor was 5.0 cm (range, 2-12cm). Single lesion and multiple foci of brain metastasis were found in 40 and 12 patients, respectively. Twenty-eight patients had extracranial metastasis simultaneously, including lung metastasis in 14 patients, liver metastasis in 13 patients, bone metastasis in 11 patients, and multiple metastases in 16 patients. The median survival was 6.7 months (range, 0.4-43.4 months), the survival rate of 6 months, 12 months and 24 months was 53.8%, 26.9%, and 4.9%, respectively. The median surviva lof craniocerebral radiotherapy group was longer than that of chemotherapy/supportive care group (8.4 months vs 2.9 months, c2= 6.706, P = 0.01). Multivariate analysis demonstrated that craniocerebral radiotherapy (P = 0.008) and Karnofsky (KPS) score (P = 0.027) were significant prognostic factors for survival. Conclusions: Approximately 0.32% of ESCC patients diagnosed or developed brain metastasis since initial registration. A higher KPS score and craniocerebral irradiation were associated with a better survival trend. Craniocerebral radiotherapy should be an importantoption for ESCC patients with brain metastasis owing to poor efficacy of systemic regimens.

PI3K Overexpression andPIK3CAMutations Are Associated with Age, Tumor Staging, and Other Clinical Characteristics in Chinese Patients with Esophageal Squamous Cell Carcinoma

2017 â—½  
Vol 21 (4) â—½  
pp. 236-241 â—½  
Author(s):  
Jing-wei Lin â—½  
Xu Li â—½  
Ming-lian Qiu â—½  
Rong-gang Luo â—½  
Jian-bo Lin â—½  
...  
Keyword(s):  
Squamous Cell Carcinoma â—½  
Esophageal Squamous Cell Carcinoma â—½  
Cell Carcinoma â—½  
Squamous Cell â—½  
Clinical Characteristics â—½  
Tumor Staging â—½  
Chinese Patients

scholarly journals Development and Validation of a Gene-panel-based Nomogram for Prediction of Lymph Node Metastasis in Esophageal Squamous Cell Carcinoma

2020 â—½  
Author(s):  
Xuejie Wu â—½  
Donglai Chen â—½  
Wenjia Wang â—½  
Fei Ye â—½  
Yonghua Sang â—½  
...  
Keyword(s):  
Squamous Cell Carcinoma â—½  
Lymph Node â—½  
Lymph Node Metastasis â—½  
Esophageal Squamous Cell Carcinoma â—½  
Cell Carcinoma â—½  
Squamous Cell â—½  
Clinical Characteristics â—½  
Gene Panel â—½  
The Cancer Genome Atlas â—½  
Node Metastasis

Abstract Background: Esophageal squamous cell carcinoma (ESCC) is one of the main histological subtypes of esophageal cancer. This study aimed to develop a gene-panel-based nomogram for identification of lymph node metastasis (LNM) in ESCC patients.Methods: RNA sequencing profiles of ESCC patients were obtained from the Gene Expression Omnibus (GEO) database and The Cancer Genome Atlas (TCGA) database. A bioinformatic approach was employed to investigate differentially expressed genes (DEGs) between ESCC patients with LNM and those without. A 4-DEGs panel was eventually identified and integrated with clinical characteristics to construct a nomogram for predicting LNM. Predictive performance of the nomogram was further evaluated by calibration curves and concordance index (C-index). Results: A total of 179 ESCC patients with 32059 genes from the GEO dataset were included. Among these genes, 3524 DEGs were correlated with lymph node involvement. Meanwhile, TCGA dataset containing 93 ESCC patients was obtained, in which 82 DEGs were selected out of 18416 genes. Among the 11 communal DEGs, four genes were identified to be (ALG3, CPOX, LMLN, PSMD2) associated with LNM. A nomogram was established by integrating the four-gene panel and three clinical characteristics including T stage, G stage and tumor location. The nomogram exhibited good performance with C-indices of 0.710 and 0.693 in the GEO and TCGA datasets, respectively. Conclusion: Our novel 4-gene-based nomogram displayed its value in prediction of LNM in ESCC patients, which may be helpful in determining treatment approach for early-stage ESCC patients.

P151 NEVER SMOKER WITH ESOPHAGEAL SQUAMOUS-CELL CARCINOMA: DIFFERENT DEMOGRAPHICS BUT COMPARABLE SUVIVAL

2019 â—½  
Vol 32 (Supplement_2) â—½  
Author(s):  
Lintis Alexandru â—½  
Voron Thibault â—½  
Drbay Vincent â—½  
Messier Marguerite â—½  
Eveno Clarisse â—½  
...  
Keyword(s):  
Squamous Cell Carcinoma â—½  
Esophageal Squamous Cell Carcinoma â—½  
Cell Carcinoma â—½  
Squamous Cell â—½  
Clinical Characteristics â—½  
Disease Free Survival â—½  
Pathological Response â—½  
Preoperative Treatment â—½  
Never Smoker

Abstract Aim To assess clinical characteristics, tumor behavior and long-term of esophageal squamous-cell carcinoma in never-smoker (NS) and smoker (or former smoker) (S) patients. Background & Methods Despite a progressive decrease in the incidence of esophageal squamous-cell carcinoma (ESCC) in Europe since decades, related to the decrease in smoking, new cases of ESCC are observed in patients who have never smoked. Similar cases are described for head and neck cancers and non-small cell lung carcinomas, for which increased radiosensitivity and favorable prognosis is described. We conducted a retrospective analysis on single-center prospectively maintained database, including all patients undergoing esophagectomy for ESCC between 2010 and 2017. The primary endpoint was overall survival(OS). Secondary endpoints included disease-free survival(DFS), pathological response to preoperative treatment according to Mandard's classification (Tumor Regression Grade; TRG) and clinical characteristics of patients. Results Three hundred and two patients underwent esophagectomy for ESCC during study period, 57 in NS group and 245 in S group. Esophageal cancers in NS patients were more frequently observed in women (68.4% vs 20%;p<0.001) and older (65.42 vs 60.69; p<0.001) than patients in S group. Tumor location (ie. cervical, upper third, middle third, lower third/EGJ) was similar between the 2 groups. Neoadjuvant radiochemotherapy was more frequently performed in S group (64.2% vs 49.1%;p=0.035) and malnutrition was less frequent in NS group (6.3% vs 20.9%;p=0.05). Tumoral characteristics (usT and usN) were comparable between the 2 groups. Pathological response to preoperative radichemotherapy was similar between NS and S group: (TRG1-2: 53.8% vs 53.7%). Postoperative complications were more frequent in S group (77.4% vs 63.2%;p=0.024), with more postoperative deaths (5.8% vs 0; p=0.080). NS patients had better OS than S patients, without reaching significance (mean survival: 46.1±4.7 months vs 35.9±2.0 months;p=0.080), and better DFS (40.0±5.3 months vs 30.0±2.1;p=0.077) Conclusion Esophageal squamous cell carcinoma in never-smoker is characterized by low male-female sex-ratio, reduced post-operative morbidity and mortality. However, pathological response to preoperative radiochemotherapy and long-term outcomes seem to remain unaffected by tobacco use.

scholarly journals Prognosis impact of clinical characteristics in patients with inoperable esophageal squamous cell carcinoma

PLoS ONE â—½  
2017 â—½  
Vol 12 (8) â—½  
pp. e0182660 â—½  
Author(s):  
Ying Yang â—½  
Jun Jia â—½  
Zhiwei Sun â—½  
Feng Du â—½  
Jing Yu â—½  
...  
Keyword(s):  
Squamous Cell Carcinoma â—½  
Esophageal Squamous Cell Carcinoma â—½  
Cell Carcinoma â—½  
Squamous Cell â—½  
Clinical Characteristics

scholarly journals Analyzing the Expression Level and Associated Clinical Characteristics of miRNA-138 in Esophageal Squamous Cell Carcinoma in Iranian Patients

2021 â—½  
Vol 30 (2) â—½  
pp. 108-117
Author(s):  
Maryam Zare â—½  
Keyword(s):  
Squamous Cell Carcinoma â—½  
Esophageal Cancer â—½  
Esophageal Squamous Cell Carcinoma â—½  
Cell Carcinoma â—½  
Squamous Cell â—½  
Clinical Characteristics â—½  
Rna Extraction â—½  
Expression Level â—½  
Aberrant Expression â—½  
Tumor Tissues

Background: Esophageal Squamous Cell Carcinoma (ESCC) is the seventh most common and lethal malignancy worldwide with a high incidence in Iran. Esophageal cancer has a poor prognosis and low 5-years survival rate. Despite several studies on esophageal cancer, its underlying mechanism remains unclear. Therefore, it is significant to analyze the molecular factors involved in disease for introducing effective diagnosis and therapeutic approaches. Accordingly, the aberrant expression of miRNA was demonstrated in the etiology of esophageal cancer, and applying them as detecting biomarkers was further considered by researchers. This study aimed to evaluate the expression level of miRNA-138 in the tumor tissues of ESCC and normal adjacent tissues. Objective: In total, 35 samples of tumor and normal tissues of the esophagus were collected from ESCC patients. Methods: Then, RNA extraction was conducted and the expression level of miRNA-138 was assessed in the collected tissue samples, applying real-time RT-PCR. Moreover, the relationship between the miRNA-138 expression level and the patient’s clinical characteristics was assessed. Results: According to the obtained results, the expression of miR-138 was significantly downregulated in the tumor tissues of ESCC, compared to normal adjacent tissues (P<0.05). Additionally, the level of miRNA-138 downregulation was significantly correlated with tumor differentiation degree and metastasis status (P<0.05). Conclusion: The significant downregulation of miRNA-138 in the tumor samples of ESCC indicated the role of this epigenetic alteration in esophageal carcinogenesis. Therefore, applying the miRNA-138 could be considered as a potential molecular biomarker for ESCC diagnosis and screening.

Sign in / Sign up

Export Citation Format

Share Document